Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ISIS 325568 in healthy volunteers
NL-OMON31095Phase 1Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Aug 2007
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, double-blind trial of ISIS 449884 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Safety and tolerability of single-dose ISIS 325568, Safety and tolerability of multiple-dose ISIS 325568 and 1 more. Started Aug 2007; status: active, not recruiting.
02
Drugs
ISIS 449884
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON31095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31095.